Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.59 |
| ▸ | FABP7 | O15540 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381061 | 1.00 | FABP5 (0.59) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL29901230 | 1.00 | FABP5 (0.59) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL30433255 | 0.93 | KMT2A (0.55) | FABP5FABP7KMT2AEPHX2CA1 | |
| Isothiocyanate SCHEMBL29261606 | 0.90 | FABP5 (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| Isothiocyanate SCHEMBL30858893 | 0.90 | FABP5 (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL44676 | 0.86 | KMT2A (0.58) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL15981181 | 0.86 | KMT2A (0.58) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL13258633 | 0.86 | FABP5 (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL7767154 | 0.86 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL29598813 | 0.86 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5428 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | claimed |
| EP-3947382-B1 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND BETA-THALASSEMIA | ACADEMIA SINICA (TW) | 2025-09-24 | — | — | EP | claimed |
| EP-4484439-A1 | 6'-CYANO-MODIFIED LOCKED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID POLYMER | Academy of Military Medical Sciences (CN) | 2025-01-01 | — | — | EP | claimed |
| WO-2024234728-A1 | 6'-CYANO-MODIFIED LOCKED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID POLYMER | 中国人民解放军军事科学院军事医学研究院 | 2024-11-21 | — | — | WO | claimed |
| CN-118791543-A | Synthesis of 3' -RNA oligonucleotides | 阿尔尼拉姆医药品有限公司 | 2024-10-18 | — | — | CN | claimed |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-13 | — | — | US | claimed |
| CN-118369427-A | Extrahepatic delivery IRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-115038790-B | Synthesis of 3' -RNA oligonucleotides | 阿尔尼拉姆医药品有限公司 | 2024-06-21 | — | — | CN | claimed |
| EP-2991655-B1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-5872101-A | Methods of treating neurodegenerative disorders using protease inhibitors | SIBIA NEUROSCIENCES, INC. (US) | 1999-02-16 | — | — | US | claimed |
| EP-0800528-A1 | PEPTIDE AND PEPTIDE ANALOG PROTEASE INHIBITORS | Sibia Neurosciences, Inc. (US) | 1997-10-15 | — | — | EP | claimed |
| US-5637759-A | Metal-ligating amino acid derivatives for MRI and for peptide synthesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-06-10 | — | — | US | claimed |
| US-5616711-A | REACTING BUTENE DERIVATIVE TO AN AMIDE DERIVATIVE; USEFUL AS INTERMEDIATES FOR PRODUCING ANTIULCER DRUGS | FUJIREBIO INC. (JP) | 1997-04-01 | — | — | US | claimed |
| WO-1996020725-A2 | PEPTIDE, PEPTIDE ANALOG AND AMINO ACID ANALOG PROTEASE INHIBITORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-07-11 | — | — | WO | claimed |
| WO-1996020949-A1 | PEPTIDE AND PEPTIDE ANALOG PROTEASE INHIBITORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-07-11 | — | — | WO | claimed |
| EP-0582304-A2 | Methods of producing amino butene derivatives | FUJIREBIO Inc. (JP) | 1994-02-09 | — | — | EP | claimed |